Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women by Kuo, W-H et al.
Cumulative survival in early-onset unilateral and bilateral breast
cancer: an analysis of 1907 Taiwanese women
W-H Kuo
1,4, AM-F Yen
2, P-H Lee
1,4, K-M Chen
1, J Wang
3, K-J Chang
1,4, TH-H Chen*,2,5 and H-S Tsau
1
1Department of Surgery, College of Medicine, National Taiwan University Hospital, No. 7, Jhongshan S. Rd., Jhongjheng District, Taipei City 100, Taiwan;
2Division of Biostatistics, Graduate Institute of Epidemiology, College of Public Health, National Taiwan University, Room 521, No.17, Hsuchow Rd.,
Jhongjheng District, Taipei City 100, Taiwan;
3Department of Radiology, College of Medicine, National Taiwan University Hospital, No. 7, Jhongshan S. Rd.,
Jhongjheng District, Taipei City 100, Taiwan;
4Angiogenesis Research Center, National Taiwan University, Room 8-46, Floor 8, No. 7, Jhongshan S. Rd.,
Jhongjheng District, Taipei City 100, Taiwan;
5Centre of Biostatistics Consultation, College of Public Health, National Taiwan University, Room 540, No.17,
Hsuchow Rd., Jhongjheng District, Taipei City 100, Taiwan
As the epidemiological pattern of breast cancer in modernising Asian countries differs greatly from that in Western countries, it is
worthwhile to investigate the long-term prognoses of unilateral and bilateral breast cancer in these nations. A retrospective cohort
study composed of 1907 Taiwanese women was conducted to follow 1863 unilateral and 44 bilateral cases of breast cancer. Time-
dependent Cox regression was used to assess the risk of breast cancer death by considering the time course of unilateral and bilateral
tumour development. The 15-year survival rates were 68.37, 62.63, and 26.42% for unilateral, synchronous bilateral, and
metachronous bilateral breast cancer, respectively. Differences among types were most apparent after 5 years of follow-up. After
adjusting for significant prognostic factors, the risk of death for overall bilateral breast cancer was 2.50-fold greater (95% CI,
1.43–4.37) compared to unilateral breast cancer. The corresponding figures were 1.12-fold (95% CI, 0.42–3.02) and 6.11-fold (95%
CI, 3.14–11.89) for synchronous and metachronous bilateral breast cancer, respectively. Taiwanese women, who are frequently
diagnosed with breast cancer before 50 years of age, showed poorer survival for metachronous bilateral than for synchronous
bilateral or unilateral breast cancer. Survival was markedly poorer compared to recent data from Sweden.
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Rising breast cancer incidence has been consistently reported in
most modernising Asian countries, including Japan, Singapore,
Hong Kong, and Taiwan (Shen et al, 2005; Sim et al, 2006; Matsuno
et al, 2007; Leung et al, 2008), even though organised mass
screening programmes, which typically lead to increased reporting
of unilateral or bilateral cancer, and adjuvant systematic treatment,
which may lead to the reduction of bilateral breast cancer, have not
been widely implemented. Moreover, in contrast to the pattern
more typically observed in Western countries, breast cancer in
modernising Asian countries occurs predominately in younger
rather than older women, (IARC, 2002; Ahn et al, 2004; Shen et al,
2005; Yang et al, 2005; Kuo et al, 2006). Because epidemiologic
profiles and the availability and implementation of breast cancer
screening and adjuvant systematic treatment programmes differ
between Asian and Western countries, it is of great interest to
assess whether incidence rates and prognoses for unilateral and
bilateral breast cancers differ between these regions. Our previous
studies in Taiwan showed that the incidence of bilateral breast
cancer increased with time after the first primary breast cancer,
and that the annual progression rate from unilateral to bilateral
breast cancer was faster than that observed in Western countries
(Kuo et al, 2006).
Regarding prognosis, previous studies comparing survival
between Western women with bilateral vs unilateral breast cancer
have yielded inconsistent results. Some studies found that bilateral
breast cancer had a poorer prognosis than unilateral breast cancer
(Alexander et al, 1989; Brenner et al, 1993; Nomura et al, 1999),
whereas others showed similar prognoses for both types (Fisher
et al, 1984; Mose et al, 1997; Newman et al, 2001). A recent large
cohort study in Sweden reported a trend of declining incidence for
synchronous bilateral cancer, similar to unilateral breast cancer,
but an increasing trend for metachronous bilateral cancer (Hart-
man et al, 2007). The authors also found that metachronous
bilateral cancer showed the highest mortality rate, followed by
synchronous bilateral cancer and then unilateral breast cancer.
(Hartman et al, 2007).
In Western studies, comparisons between unilateral and
bilateral breast cancers are frequently based on cases diagnosed
at greater than 50 years, of age; for this reason, relatively little is
known regarding survival profiles for early-onset unilateral and
bilateral breast cancers, which are frequently observed in
modernising Asian countries. By following up with a previously
described cohort of Taiwanese women with unilateral and bilateral
breast cancers (which showed a preponderance of young women;
Kuo et al, 2006), this study offers an opportunity to compare
cumulative survival rates between unilateral and bilateral breast
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scancers while controlling for other prognostic factors associated with
the risk of death using a time-dependent Cox regression model.
PATIENTS AND METHODS
Study subjects
A total of 1907 Taiwanese women with breast cancer, including
1863 unilateral and 44 bilateral cases of breast cancer, were
recruited from among the patients treated at the National Taiwan
University Hospital. All patients had been diagnosed with primary
breast cancer between 1990 and 1999. Patients with bilateral breast
cancer were further divided into two groups, synchronous and
metachronous, with an interval between the first and contralateral
breast cancer of p6 months and 46 months, respectively. The
mean (median) time until diagnosis of metachronous breast cancer
was 3.03 (2.80) years. Because we had no data on the date of one
patient’s second diagnosis, only 43 patients were considered when
synchronous and metachronous bilateral breast cancers were
analysed separately. Basic characteristics and clinicopathological
details were collected using the procedure for bilateral breast cancer
cases described in detail elsewhere (Kuo et al,2 0 0 6 ) .T h et r e a t m e n t
guideline for breast cancer follows the guideline set up by the
organisation, called Taiwan Cooperative Oncology Group, which has
been supported by the National Health Research Institute. The
guidelines for breast cancer include surgery, adjuvant therapy, and
surveillance schedule for different staging of breast cancer (http://
english.nhri.org.tw/inst_cancer/ca_TCOG.php).
Study design and data collection
A retrospective cohort study was designed to follow these 1907
breast cancer cases until 31 December 2004. The main variable of
interest was the type of breast cancer (unilateral, metachronous
bilateral, or synchronous bilateral). The primary end point was
death from breast cancer. The mean follow-up time was
7.8±(s.d.), 3.8 years for all patients, compared to 7.9±3.8 years,
7.0±5.0 years, and 6.6±3.7 years for unilateral, synchronous
bilateral, and metachronous bilateral cases, respectively.
Regarding confounding variables, a research assistant retro-
spectively retrieved information from medical charts. Data on
demographic features, anthropometric measurements, reproduc-
tive factors (e.g., number of pregnancies, deliveries, and
abortions), personal history of cancer and breast disease, family
history of breast cancer among first- or second-degree relatives,
and previous surgery or use of hormones were collected.
Information on tumour attributes and surgical findings were first
reviewed by the research assistant and then confirmed by
specialists.
Statistical analysis
The Wilcoxon’s rank sum test was used to test differences in mean
values for continuous variables between two groups. The w
2 test
was used to compare categorical variables between groups, and the
Fisher’s exact test was applied if a sparse number in a specific cell
was encountered. Cumulative survival was plotted for unilateral
and bilateral (synchronous or metachronous) cancers using the
Kaplan Meier method. The log-rank test was used to determine
whether differences among types of breast cancer were statistically
significant. We used the indicator method to deal with covariates
with missing values in the Cox regression model (Greenland and
Finkle, 1995).
Figure 1 illustrates why a time-dependent Cox regression model
is required to compare cumulative survival between unilateral and
bilateral breast cancer. Women with bilateral breast cancer had
two dates of diagnosis, one for the primary tumour (A1B) and one
for the contralateral tumour (A2B); the duration between A1B and
A2B is the interval between the first and second breast tumours,
called waiting period for the development of the second cancer of
bilateral type. D refers to breast cancer death, loss to follow-up, or
the end of study. Thus, two survival intervals were defined for
women with bilateral breast cancer (D A1B and D A2B), but only
one (D A1U) for women with unilateral breast cancer. Because the
comparison between unilateral (code¼0) and bilateral breast
cancer (code¼1) should be made on the basis of D A1B, the
status (code¼0) regarding the waiting period between the first of
two breast tumours and the second (A2B–A1B) should be treated as
if they are unilateral. The status (code¼1) is then altered to
bilateral breast cancer once the second is developed. Note that all
tumour attributes corresponding to the first and second tumours
and adjuvant treatments indicated by the physician during the first
and second follow-up periods were treated as time-dependent
covariates. The association between each relevant variable and the
risk of death was assessed through univariate analysis. All
significant variables in the univariate analysis were entered into
the multivariate analysis. To optimise statistical efficiency, a
parsimonious model was created using only variables retaining
statistical significance after adjustment for all other relevant
variables. Crude and adjusted hazard ratios (HRs) and their 95%
confidence intervals were computed in univariate and multivariate
analyses. The level of statistical significance was set at 5%.
RESULTS
Table 1 summarises demographic characteristics and reproductive
and lifestyle factors for the study cohort. The mean ages at
diagnosis in women with bilateral and unilateral breast cancers
were 48.7±10.0 and 49.8±12.2 years, respectively; women with
metachronous bilateral cancer showed the youngest age at onset
(48.5±11.2 years). With the exception of family history, the
remaining variables were not significantly associated with type of
breast cancer. Women with a family history of breast cancer were
more likely to develop contralateral breast cancer than women
without.
After 15 years of follow-up, the case fatality rate was lower in
unilateral breast cancer (27.6%, 514 out of 1863) compared to
synchronous bilateral breast cancer (35.3%, 6 out of 17) and
metachronous bilateral breast cancer (61.5%, 16 out of 26).
Figure 2 shows cumulative survival rates according to breast
cancer type. Metachronous breast cancer was associated with the
poorest survival rate, followed by synchronous breast cancer,
compared to unilateral breast cancer. The 15-year survival rates
were 68.4, 62.6, and 26.4% for unilateral, synchronous bilateral,
and metachronous bilateral breast cancer, respectively, and this
difference was statistically significant (Po0.01). However, the
disparity between unilateral and metachronous bilateral cancer
Bilateral  
Age of diagnosis
First breast cancer
A2B A1B D
Breast cancer
death or censoring 
Unilateral
A1u
Breast cancer
death or censoring 
A2B−A1B: Interval before developing contralateral breast cancer 
D−A1B: Survival time for first of two breast tumours 
D−A2B: Survival time for second of two breast tumours 
D-A1u: Survival time for unilateral breast cancer 
Age of diagnosis
Second breast cancer
D 
Figure 1 Time-dependent analysis of unilateral and bilateral breast
cancer.
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swas larger than that between unilateral and synchronous bilateral
breast cancer. The difference was most apparent after 5 years of
follow-up. Interestingly, remarkably divergent time points
occurred at approximately 3 years for unilateral and synchronous
bilateral breast cancer and at 6 years for metachronous and
synchronous bilateral breast cancer, implying that the average
interval for developing contralateral breast cancer was approxi-
mately 3 years. Figure 3 shows cumulative survival for unilateral,
synchronous, and metachronous cancer, as well as the interval
between the diagnosis of the first and second tumours in women
with metachronous bilateral breast cancer. Women in whom the
second metachronous tumour was diagnosed within 3 years
showed the poorest survival. It is also noted that Figures 2 and 3
show how hazard rates changed with time by types of breast
cancer. The patterns of trend by type of breast cancer were
consistent with the survival profiles.
The frequencies of clinical attributes according to type of breast
cancer are listed in Table 2. Bilateral breast cancer patients were
less immunoreactive for the oestrogen receptor than were
unilateral breast cancer patients (P¼0.04). Oestrogen receptor
negativity was most prominent in patients with synchronous
bilateral breast cancer (P¼0.03). Synchronous breast cancer also
showed a higher likelihood of being negative for the progesterone
receptor (P¼0.08). In bilateral breast cancer, metachronous cases
had a higher likelihood of axillary lymph node involvement
compared to synchronous cases (P¼0.02). The likelihood of local
recurrence (P¼0.02) was higher in bilateral than in unilateral
cases. Patients with metachronous bilateral breast cancer were
more likely to have local recurrence (P¼0.03) and distant
metastasis (P¼0.01) than those with synchronous cancer.
Table 3 shows the crude and adjusted HRs for relevant variables.
Women with bilateral breast cancer had a 3.27-fold (95% CI,
2.15 4.97) greater risk of death compared to those with unilateral
breast cancer. In the multivariate analysis, only the type of breast
cancer, histological type, chemotherapy (only adjusted in the
model analysing synchronous and metachronous bilateral breast
cancer separately), tumour size, and regional lymph node
involvement remained statistically significant after adjusting for
significant variables. After controlling for these four variables, the
HRs for death due to overall bilateral, synchronous bilateral, and
Table 1 Distributions of demographic, lifestyle, and reproductive features of unilateral and bilateral breast cancer cases, at time of first diagnosis
Bilateral
Unilateral (N¼1863) Synchronous (N¼17) Metachronous (N¼26) Overall (N¼43)
Variable No. % No. % No. % No. % P-value
a P-value
b
Age(years)
c 49.8±12.2 (47.9) 49.0±8.1 (46.1) 48.5±11.2 (50.1) 48.7±10.0 (49.5) 0.85 0.95
BMI 23.4±3.6 22.8±4.1 22.4±2.9 22.6±3.4 0.34 0.83
Education (%) 0.68 0.48
College or above 382 27.3 4 33.3 3 21.4 7 26.9
Senior high school 340 24.3 3 25.0 1 7.1 4 15.4
Junior high school 181 12.9 1 8.3 4 28.6 5 19.2
Elementary school 351 25.1 3 25.0 3 21.4 6 23.1
Illiterate 144 10.3 1 8.3 3 21.4 4 15.4
Age at menarche 14.4±1.7 14.1±1.6 14.6±1.8 14.4±1.7 0.91 0.29
Menopause 0.07 0.70
Yes 739 55.8 8 66.7 15 75.0 23 71.9
No 585 44.2 4 33.3 5 25.0 9 28.1
Age of menopause 48.4±5.3 49.3±4.9 48.3±6.4 48.7±5.9 0.69 0.52
Hysterectomy 0.78 1.00
Yes 146 8.4 1 5.9 3 11.5 4 9.3
No 1585 91.6 16 94.1 23 88.5 39 90.7
Pregnancy 3.3±2.2 2.5±1.3 3.0±2.2 2.8±1.8 0.26 0.49
Childbirth 2.6±1.7 2.1±1.2 2.4±1.6 2.2±1.4 0.41 0.48
Miscarriage 0.7±1.1 0.4±0.6 0.6±1.1 0.5±0.9 0.33 0.91
Age of first childbirth 25.5±4.6 23.5±3.9 25.9±5.6 25.0±5.0 0.41 0.34
Breast feeding 0.15 0.34
Yes 420 60.8 1 20.0 7 50.0 8 42.1
No 271 39.2 4 80.0 7 50.0 11 57.9
Smoking 1.00 1.00
Yes 47 2.6 0 0.0 1 4.2 1 2.6
No 1739 97.4 15 100.0 23 95.8 38 97.4
Drinking 0.65 0.14
Yes 65 3.6 2 13.3 0 0.0 2 5.1
No 1722 96.4 13 86.7 24 100.0 37 94.9
Family history of
breast cancer
0.05 1.00
Yes 86 4.6 2 11.8 3 11.5 5 11.6
No 1777 95.4 15 88.2 23 88.5 38 88.4
aUnilateral vs Bilateral.
bSynchronous vs Metachronous.
cThe medium age was reported in the bracket.
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smetachronous bilateral breast cancer were 2.50 (95% CI,
1.43 4.37), 1.12 (95% CI, 0.42 3.02), and 6.11 (95% CI,
3.14 11.89) compared to unilateral breast cancer.
DISCUSSION
Prognosis for unilateral and bilateral breast cancer in
Asian countries
Complete follow-up data on the prognoses of unilateral and
bilateral breast cancer in modernising Asian countries is scanty.
For this reason, we conducted a long-term, longitudinal, follow-up
study to examine demographic data, conventional risk factors,
tumour attributes, systematic adjuvant therapy, and family history
in a cohort of Taiwanese women. Our study demonstrates that
patients in Taiwan with bilateral breast cancer, particularly of the
metachronous type, showed poorer survival. In Taiwan, breast
cancer is frequently diagnosed before 50 years of age (Kuo et al,
2006) and Taiwanese women with bilateral tumours face a 6-fold
greater risk of death compared to women with unilateral breast
cancer, after controlling for lymph node status, tumour size,
histological type, and positive family history. The corresponding
risk increased to 8-fold (95% CI, 3.00–23.32, Po0.0001) after
further adjustment for age at diagnosis, adjuvant therapy, and
progesterone and oestrogen status, although none of these was
statistically significant in the multivariate analysis. These results
suggest that poor survival in bilateral breast cancer patients cannot
entirely be accounted for by family history, lack of adjuvant
therapy, unfavourable tumour attributes (i.e., tumour size,
lymph node status, and histological type), late detection, or
other factors. Poor survival in bilateral cancer patients indepen-
dent of unfavourable tumour attributes due to late diagnosis
was also reported by Kollias et al (2001); in this previous
study, bilateral breast cancer showed a 1.67-fold greater risk of
death after adjustment using the Nottingham Prognostic
Index, which considers tumour size, histological grade, and
lymph node status. It is thought that survival rates are affected
by other factors, such as access to medical care and lifestyle
factors. However, these factors are unlikely to have had a
significant effect in our analysis because they were similar across
groups (Table 2).
After ruling out the possibilities mentioned above, a difference
in survival remained, making it difficult to explain why bilateral
breast cancer is associated with poorer survival compared to
unilateral breast cancer. This may be partially explained by genetic
reason. In our study, women with bilateral breast cancer had
higher proportion of having family history than those with
unilateral breast cancer when family history is a significant
predictor for poor prognosis. The genetic susceptibility may also
account for why synchronous breast cancer showed better survival
than metachronous breast cancer. Women with metachronous
bilateral breast cancer showed earlier onset than women with
unilateral or synchronous bilateral cancer, and an interval of less
than 3 years between metachronous tumours was associated with
poor survival. Thus, in a country where breast cancer is frequently
diagnosed in women of less than 50 years of age, poor survival may
be attributed to metachronous bilateral cancers. Based on our
results, we recommend that the inter-examination interval for
unilateral breast cancer should not exceed 18 months (assuming
uniform distribution of developing contralateral breast cancer).
However, to prove the possibility of genetic susceptibility in
relation to any survival difference across type of breast cancer
molecular genetic studies such as BRCA1 and BRCA2 in
association with survival, although the results are inconsistent
(Moller et al, 2007; Rennert et al, 2007; Tutt and Ashworth, 2008),
are still required.
Comparison with findings from Western nations
The prevalence of young breast cancer patients in Asian countries
may indicate that these women show distinct clinical profiles
regarding the prognoses of unilateral and bilateral breast cancer. A
comparison between our study and that of Hartman et al (2007)
showed that the 10-year survival for metachronous bilateral
breast cancer patients was markedly poorer among Taiwanese
women (40%) compared to Swedish women (60%), whereas
the corresponding figures for unilateral and synchronous
bilateral breast cancers were similar. Because Hartman et al
(2007) found a higher mortality rate for metachronous bilateral
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Figure 3 Cumulative breast cancer-specific survival rates for unilateral,
synchronous bilateral, and metachronous bilateral breast cancers.
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sbreast cancer in women younger than 50 years old, it stands to
reason that the relatively poor survival among patients with
metachronous bilateral breast cancer in our study is the result of a
disproportionately large number of young breast cancer patients in
our cohort. One may also speculate whether such a difference of
survival is related to local recurrence and the finding of ER status.
In Table 2, we have demonstrated metachronous cancer is more
likely to show local recurrence and the greater frequency of
ER-positive among metachronous cancer patients. The latter
finding is consistent with the results of poor prognosis among
Table 2 Distributions of clinical attributes and adjuvant therapies used in unilateral and bilateral breast cancer cases, at the time of first diagnosis
Bilateral
Unilateral (N¼1863) Synchronous (N¼17) Metachronous (N¼26) Overall (N¼43)
Variable No. % No. % No. % No. % P-value
a P-value
b
Tumour size (cm) 3.3±3.7 4.0±2.8 3.5±2.0 3.7±2.3 0.33 0.48
T1 (p2) 0.48 0.67
T1a (p0.5) 16 0.9 0 0.0 0 0.0 0 0.0
T1b (0.5 1.0) 100 5.9 2 13.3 1 5.0 3 8.6
T1c (1.0 2.0) 464 27.2 3 20.0 6 30.0 9 25.7
T2 (2.0 5.0) 922 54.1 6 40.0 10 50.0 16 45.7
T3, T4 (45) 201 11.8 4 26.7 3 15.0 7 20.0
Histology type 0.18 0.13
IDC 1558 85.4 12 80.0 25 96.2 37 90.2
DCIS 106 5.8 2 13.3 1 3.8 3 7.3
ILC 30 1.6 1 6.7 0 0.0 1 2.4
Others 130 7.1 0 0.0 0 0.0 0 0.0
Grade 0.72 0.68
1 126 29.7 2 66.7 1 20.0 3 37.5
2 206 48.6 1 33.3 2 40.0 3 37.5
3 92 21.7 0 0.0 2 40.0 2 25.0
Oestrogen receptor 0.04 0.03
Positive 871 64.2 4 26.7 12 63.2 16 47.1
Negative 485 35.8 11 73.3 7 36.8 18 52.9
Progesterone receptor 0.23 0.08
Positive 788 60.2 5 33.3 12 63.2 17 50.0
Negative 521 39.8 10 66.7 7 36.8 17 50.0
Chemotherapy 0.13 0.74
Yes 1080 59.8 12 75.0 18 69.2 30 71.4
No 725 40.2 4 25.0 8 30.8 12 28.6
Radiotherapy 0.12 1.00
Yes 164 10.0 3 18.8 4 16.7 7 17.5
No 1480 90.0 13 81.2 20 83.3 33 82.5
Tamoxifen 0.31 0.71
Yes 1444 81.4 12 80.0 18 72.0 30 75.0
No 331 18.6 3 20.0 7 28.0 10 25.0
Axillary lymph node metastasis 0.49 0.02
Yes 599 44.3 4 26.7 15 65.2 19 50.0
No 753 55.7 11 73.3 8 34.8 19 50.0
Local recurrence 0.02 0.03
Yes 203 11.2 1 5.9 9 36.0 10 23.8
No 1607 88.8 16 94.1 16 64.0 32 76.2
Distant metastasis 1.00 0.01
Yes 371 20.5 0 0 8 32.0 8 19.0
No 1439 79.5 17 100 17 68.0 34 81.0
Metastatic sites
Bone 187 11.2 0 0.0 3 13.6 3 7.7 0.80 0.24
Lung 181 10.9 0 0.0 4 17.4 4 10.0 1.00 0.12
Liver 169 10.2 0 0.0 0 0.0 0 0.0 0.045 —
Brain 64 4.1 0 0.0 0 0.0 0 0.0 0.50 —
Neck LN 63 4.0 0 0.0 4 17.4 4 10.0 0.08 0.12
DCIS¼ductal carcinoma in situ;I D C¼infiltrating ductal carcinoma; ILC¼infiltrating lobular carcinoma.
aUnilateral vs Bilateral.
bSynchronous vs Metachronous.
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syoung women with ER-positive breast tumour in comparison to
negative hormonal profiles (Aebi et al, 2000; Ahn et al, 2007;
Anders et al, 2008).
Strength of study
One of the major merits of our study is the application of a time-
dependent survival model. The rationale for using time-dependent
Cox regression model is two-fold. First, this method overcomes the
problem of selective survival for those who have survived longer and
developed a second tumour in comparison to those who had the
potential to develop bilateral tumours but did not do so before dying
or reaching the end of the study period. As illustrated in Figure 1,
which shows survival time without considering the altered status, the
interval D A1B for bilateral breast cancer is greater than D A1U for
unilateral breast cancer. However, if a waiting period is taken into
account, the survival time for bilateral breast cancer would be shorter
than that for unilateral breast cancer. The HR for metachronous
bilateral breast cancer compared to unilateral breast cancer decreased
to 3.11 (95% CI, 1.60–6.04) when a time-dependent covariate for
type of breast cancer was not used. The second advantage of using
Table 3 Crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for prognostic factors associated with the risk of breast cancer death
Crude HR Adjusted HR (CR)
a Adjusted HR (CR)
b
P-value P-value P-value
Age at first onset (years) 0.1927
o35 1.23 (0.93 1.62) 0.15 1.20 (0.78 1.84)
35 44 0.94 (0.77 1.13) 0.50 0.81 (0.60 1.09)
X45 1.00 — 1.00 —
Type
Unilateral 1.00 — 1.00 — 1.00 —
Bilateral 3.27 (2.15 4.97) o0.0001 3.04 (1.97 4.69) o0.0001 2.50 (1.43 4.37) 0.001
Type 2 0.0002 o0.0001
Unilateral 1.00 — 1.00 — 1.00 —
Synchronous 1.52 (0.68 3.40) 0.31 2.91 (0.40 21.46) 1.12 (0.42 3.02)
Metachronous 5.68 (3.45 9.37) o0.0001 8.35 (2.99 23.32) 6.11 (3.14 11.89)
Histology type 0.0013 0.0206
IDC 0.98 (0.73 1.30) 0.88 1.00 (0.74 1.35) 0.92 (0.69 1.24)
DCIS 0.23 (0.12 0.47) 0.23 0.27 (0.13 0.54) 0.34 (0.17 0.69)
ILC 1.30 (0.68 2.49) 0.43 1.16 (0.60 2.23) 1.15 (0.60 2.22)
Others 1.00 — 1.00 — 1.00 —
Oestrogen receptor
  1.00 — 1.00 —
+ 0.74 (0.61 0.91) 0.004 0.80 (0.59 1.08) 0.15
Progesterone receptor
  1.00 — 1.00 —
+ 0.78 (0.64 0.96) 0.02 0.77 (0.57 1.03) 0.08
Chemotherapy
  1.00 — 1.00 —
+ 3.36 (2.70 4.20) o0.0001 1.40 (0.98 1.98) 0.06
Radiotherapy
  1.00 — 1.00 —
+ 1.49 (1.14 1.95) 0.004 1.11 (0.73 1.70) 0.62
Tamoxifen
  1.00 — 1.00 —
+ 1.28 (1.00 1.63) 0.047 1.33 (0.93 1.89) 0.12
Axillary lymph node metastasis
  1.00 — 1.00 — 1.00 —
+ 4.10 (3.24 5.18) o0.0001 2.56 (1.84 3.56) o0.0001 3.43 (2.67 4.42) o0.0001
Size (cm)
o2 1.00 — 1.00 — 1.00 —
X2 2.50 (1.84 3.38) o0.0001 1.59 (1.06 2.39) 0.02 1.85 (1.30 2.62) 0.0006
Family history
  1.00 — 1.00 — 1.00 —
+ 1.44 (1.02 2.03) 0.04 1.42 (1.01 2.01) 0.04 1.49 (1.06 2.11) 0.02
DCIS¼ductal carcinoma in situ;I D C¼infiltrating ductal carcinoma; ILC¼infiltrating lobular carcinoma.
aControlling for all variables.
bControlling for significant variables in multivariate
analysis, including type of breast cancer, histology type of breast cancer, tumour size, regional lymph node involvement, and family history when overall bilateral breast cancer was
compared with unilateral breast cancer; chemotherapy was also considered when metachronous and synchronous breast cancer were compared with unilateral breast cancer. Note
that the adjusted HRs for the controlling variables provided in Table 3 were based on the model comparing overall bilateral breast cancer and unilateral breast cancer.
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stime-dependent Cox regression model is to account for time-
dependent covariates. (i.e., tumour attributes, and adjuvant therapy
for the first tumour of bilateral breast cancer may be different from
the second adjuvant therapy (EBCTCG, 2005a,b)). This justified for
using time-dependent Cox regression model.
Questions may be raised regarding the relatively small sample
size examined here; however, such small cohorts cannot be
avoided in Asian countries where the baseline bilateral breast
cancer incidence remains relatively low. In contrast, in Sweden,
Hartman et al (2007) were able to analyse a relatively large cohort
of 6,550 bilateral breast cancer cases. After controlling for other
significant prognostic factors, our results based on multivariate
time-dependent Cox regression model still show statistically
significant results for the difference of survival across unilateral
and bilateral breast cancer types, given a significant statistical level
and 95% confidence interval not including 1 for adjusted hazard
ratios. We do not think statistical power is a serious problem.
Admittedly, however, our small sample may have created a greater
degree of variation in our results. Consequently, further large-scale
studies in Asian nations are required to validate our results.
Implications for regions with low incidence but
predominantly young onset
Despite a number of studies on the prognosis of unilateral and
bilateral breast cancer in Western countries, our study may have
significant implications for modernising Asian nations in which
the incidence of unilateral breast cancer is high and post-
menopausal women are predominantly affected. In developing
Asian nations, women between the ages of 45 and 54 show the
highest incidence of breast cancer; in contrast, women above the
age of 65 are more commonly affected in the United States and the
United Kingdom (IARC, 2002). The reasons for these distinct
epidemiological patterns remain obscure, but three possibilities
have been proposed. The first hypothesis is that older Asian
women are less susceptible to breast cancer than young Asian
women because of their relatively lower lifetime oestrogen
exposure. That is, older Asian women are more likely to have
experienced late menarche, earlier age at first full-term pregnancy,
higher number of births, earlier menopause, and low utilisation of
oral contraceptive pills or hormone replacement therapies
compared to their younger counterparts, who have received
oestrogen exposure similar to that experienced by women living
in Western nations. Such a cohort-driven effect has been
demonstrated in several modernising Asian studies (Seow et al,
1996; Minami et al, 2004; Chia et al, 2005; Shen et al, 2005).
The second hypothesis is that early age at diagnosis may
indicate that young Asian women are more likely to be genetically
predisposed to breast cancer. The higher risk for breast cancer in
young women among the Jews has been found to be associated
with genetic predisposition (FitzGerald et al, 1996; Rubinstein,
2004). However, this postulate has been refuted by migration
studies examining second generation Japanese migrant
women, who show breast cancer rates similar to those of Caucasian
women, but different from those of native Japanese women
(Ziegler et al, 1993; Matsuno et al, 2007). Environmental
factors have also been implicated by a second migration study
showing that American-born Asian-Americans experienced earlier
menarche than Asian women who immigrated to the USA (Shen
et al, 2005).
The third hypothesis is that the age distribution of breast cancer
patients in Western countries may be affected by the more
frequent use of mammography among older women compared to
younger women. However, the vast majority of modernising Asian
countries lack population-based mammography screening. This
may partly account for why breast cancer clusters peak around
60–69 years in Western countries.
These biological features together with the implementation of
screening and systematic adjuvant treatment programmes suggest
that the prognoses of unilateral and bilateral breast cancers in
modernising Asian countries are distinct from those observed in
Western nations.
In conclusion, metachronous bilateral breast cancers,
particularly those that develop within an interval of less than 3
years, have a poorer prognosis than synchronous bilateral and
unilateral breast cancers among Taiwanese women even after
adjustment for tumour size, nodal involvement, and histological
type. Survival among Taiwanese metachronous bilateral breast
cancer patients was also lower than survival among patients in
Sweden. Our results emphasise the importance of identifying those
with the potential to develop metachronous bilateral breast cancer
within 3 years after developing unilateral breast cancer.
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